Tests new drug candidates against placebo in adults with moderate to severe atopic dermatitis
Tests GHZ339 against placebo in adults with moderate to severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Key facts
- Where
- Edmonton, Hamilton, Markham, Montreal, and Verdun, CanadaSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06947993, who can take part
Where in Canada
- EdmontonEdmonton, CanadaNo longer taking part
- HamiltonHamilton, CanadaTaking people
- MarkhamMarkham, CanadaTaking people
- MontrealMontreal, CanadaTaking people
- VerdunVerdun, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06947993EU 2024-519081-49-00
- Record updated
- 28 September 2026
- Original description
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Inclusion: Able and willing to sign the informed consent (IC); Patients with a diagnosis of AD and onset of disease for at least 1 year; Moderate to severe AD.
Exclusion: Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol); Participant with any other active inflammatory skin disease; Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension); Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma); Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements; Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG.